Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Industry Perspective on Artificial Intelligence/Machine Learning in Pharmacovigilance
Raymond Kassekert, Neal Grabowski, Denny Lorenz, et al.
Drug Safety (2022) Vol. 45, Iss. 5, pp. 439-448
Open Access | Times Cited: 22

Showing 22 citing articles:

The Coming of Age of AI/ML in Drug Discovery, Development, Clinical Testing, and Manufacturing: The FDA Perspectives
Sarfaraz K. Niazi
Drug Design Development and Therapy (2023) Vol. Volume 17, pp. 2691-2725
Open Access | Times Cited: 45
The Use of Artificial Intelligence in Pharmacovigilance: A Systematic Review of the Literature
Maribel Salas, Jan Petracek, Priyanka Yalamanchili, et al.
Pharmaceutical Medicine (2022) Vol. 36, Iss. 5, pp. 295-306
Closed Access | Times Cited: 43
ChatGPT in medicine: A cross-disciplinary systematic review of ChatGPT’s (artificial intelligence) role in research, clinical practice, education, and patient interaction
Afia Fatima, Muhammad Ashir Shafique, Khadija Alam, et al.
Medicine (2024) Vol. 103, Iss. 32, pp. e39250-e39250
Open Access | Times Cited: 10
Trustworthy Artificial Intelligence in Dentistry: Learnings from the EU AI Act
Maxime Ducret, Elinor Wahal, D. Gruson, et al.
Journal of Dental Research (2024) Vol. 103, Iss. 11, pp. 1051-1056
Closed Access | Times Cited: 6
Digital Technology Applications in the Management of Adverse Drug Reactions: Bibliometric Analysis
Olena Litvinova, Andy Wai Kan Yeung, Fabian Peter Hammerle, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 395-395
Open Access | Times Cited: 5
Might We Come Together on a Paradigm Shift to Manage ICSRs with a Decentralized Data Model?
L.A. Rollins‐ Smith, Michael Gläser, Dieter Kempf, et al.
Drug Safety (2025)
Open Access
Towards Intelligent Automation (IA): Literature Review on the Evolution of Robotic Process Automation (RPA), its Challenges, and Future Trends
Julia Siderska, Lili Aunimo, Thomas Süße, et al.
Engineering Management in Production and Services (2023) Vol. 15, Iss. 4, pp. 90-103
Open Access | Times Cited: 14
Assessment of the efficiency of a Chat GPT®-based tool, MyGenAssist®, in an industry pharmacovigilance department for case documentation: a cross-over study (Preprint)
Alexandre Benaïche, Ingrid Billaut-Laden, Herivelo Randriamihaja, et al.
Journal of Medical Internet Research (2025) Vol. 27, pp. e65651-e65651
Open Access
Narrative Search Engine for Case Series Assessment Supported by Artificial Intelligence Query Suggestions
Alem Zekarias, Eva-Lisa Meldau, Shachi Bista, et al.
Drug Safety (2025)
Open Access
Artificial Intelligence and Machine Learning for Safe Medicines
Andrew Bate, Yuan Luo
Drug Safety (2022) Vol. 45, Iss. 5, pp. 403-405
Open Access | Times Cited: 14
An industry perspective on the use of machine learning in drug and vaccine safety
Jeffery L. Painter, Raymond Kassekert, Andrew Bate
Frontiers in Drug Safety and Regulation (2023) Vol. 3
Open Access | Times Cited: 8
Performance and Reproducibility of Large Language Models in Named Entity Recognition: Considerations for the Use in Controlled Environments
Juergen Dietrich, André Hollstein
Drug Safety (2024)
Open Access | Times Cited: 2
Adopting Artificial Intelligence in ITIL for Information Security Management—Way Forward in Industry 4.0
Manikandan Rajagopal, S. Ramkumar
Advanced technologies and societal change (2023), pp. 113-132
Closed Access | Times Cited: 3
Trustworthy AI for safe medicines
Jens‐Ulrich Stegmann, Rory Littlebury, Markus Trengove, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 10, pp. 855-856
Open Access | Times Cited: 3
Artificial intelligence in pharmacovigilance: A regulatory perspective on explainability
Luís Pinheiro, Xavier Kurz
Pharmacoepidemiology and Drug Safety (2022) Vol. 31, Iss. 12, pp. 1308-1310
Closed Access | Times Cited: 4
A Science-Based Methodology Framework for the Assessment of Combination Safety Risks in Clinical Trials
Andriani C. Patera, Julie Maidment, Brijesh Maroj, et al.
Pharmaceutical Medicine (2023) Vol. 37, Iss. 3, pp. 183-202
Open Access | Times Cited: 2
Provision and Characterization of a Corpus for Pharmaceutical, Biomedical Named Entity Recognition for Pharmacovigilance: Evaluation of Language Registers and Training Data Sufficiency
Juergen Dietrich, Philipp Kazzer
Drug Safety (2023) Vol. 46, Iss. 8, pp. 765-779
Open Access | Times Cited: 2
Advanced Applications of Artificial Intelligence in Pharmacovigilance: Current Trends and Future Perspectives
Yogesh S. Ahire, Jayesh H Patil, Harshita N Chordiya, et al.
Journal of Pharmaceutical Research (2024) Vol. 23, Iss. 1, pp. 23-33
Open Access
Artificial intelligence: A regulatory perspective
Francisco Branco, João Sousa
Elsevier eBooks (2024), pp. 43-81
Closed Access
Governance of artificial intelligence and machine learning in pharmacovigilance: what works today and what more is needed?
Michael Gläser, Rory Littlebury
Therapeutic Advances in Drug Safety (2024) Vol. 15
Open Access
Editorial: AI/ML in pharmacovigilance and pharmacoepidemiology
Wen Zou, Pantelis Natsiavas, Assaf Gottlieb
Frontiers in Drug Safety and Regulation (2024) Vol. 4
Open Access
New Technologies in Electronic Pharmacovigilance Systems for Marketing Authorisation Holders
O. A. Loginovskaya, V. P. Kolbatov, R. V. Sukhov, et al.
Safety and Risk of Pharmacotherapy (2022) Vol. 10, Iss. 3, pp. 230-239
Open Access | Times Cited: 1
Page 1

Scroll to top